Rough Rice (CBOT) (RR)

La cadena de opciones muestra datos clave de las opciones de acciones de Richtech Robotics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Richtech Robotics..

Richtech Robotics (NASDAQ:RR) Bolsa, Cadena de Opciones

Richtech Robotics

Richtech Robotics Inc is a developer of new robotic technologies focused on transforming labor-intensive services in hospitality and other sectors currently experiencing unprecedented labor shortages. The company designs, manufacture and sells robots to restaurants, hotels, senior living centers, casinos, factories, movie theaters and other businesses. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company designs its robots to be friendly, customizable to client environments, and extremely reliable.

Pre-Market Outlook

Markets

Movers

ACON

AEON

BCTX

CPHC

EKSO

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

KITT

LDTC

MBOT

MEGL

MNSO

NSTS

SPPL

WFCF

Explora los mayores movimientos en el premercado con ganancias superiores al 100% y pérdidas significativas antes de la apertura.

Acciones de Smart Share Global se disparan un 44%; 20 acciones que se mueven en el premercado

Earnings

News

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

Richtech Robotics Inc. - Class B Common Stock

Richtech Robotics Inc

RIGEL RESOURCE ACQUISITION CORP ORD

RIGEL RESOURCE ACQ CORP by Rigel Resource Acquisition Corp.

Rigel Resource Acquisition Corp

RIGEL RESOURCE ACQ CP UTS by Rigel Resource Acquisition Corp.

Rigel Resource Acquisition Corp Warrants (01/01/9999)

Red River Bancshares, Inc. - Common Stock

Red River Bancshares Inc

Range Resources Corp

ROYAL ROAD MINERALS LTD by Royal Road Minerals Limited

Royal Road Minerals Ltd

REGAL RL EST INVT TR UTS by Regal Real Estate Investment Trust

Regal Real Estate Investment Trust

ROBINSONS RTL HLG UNS/ADR by Robinsons Retail Holdings Inc.

Robinsons Retail Holdings Inc

Red Robin Gourmet Burgers, Inc. - Common Stock

Red Robin Gourmet Burgers Inc

REALITY RACING INC by Reality Racing, Inc.

Reality Racing Inc

Advisors Inner Circle Fund III Advocate Rising Rate Hedge ETF

RENRUI HUMAN RES TECH by Renrui Human Resources Technology Holdings Ltd.

Renrui Human Resources Technology Holdings Ltd

RAINFOREST RESOURCES INC by Rainforest Resources Inc.

Rainforest Resources Inc

Reach Resources Ltd

ROSS RIVER MINERALS by Ross River Minerals Inc.

Ross River Minerals Inc

Roots Corp

RE Royalties Ltd

Red Rock Resorts, Inc. - Class A Common Stock

Red Rock Resorts Inc

ROCK RIDGE RESOURCES INC by Rock Ridge Resources, Inc.

Rock Ridge Resources Inc

Rockridge Resources Ltd Shs

R-THREE TECHNOLOGIES INC by R-Three Technologies, Inc.

R-Three Technologies Inc

R&R REAL ESTATE INVT UTS by R&R REAL ESTATE INVT TR

R&R Real Estate Investment Trust

ARETTO WELLNESS INC by Aretto Wellness Inc.

Aretto Wellness Inc

Neometals Ltd

MAGNETITE MINES LTD by Magnetite Mines Ltd.

Magnetite Mines Ltd

Recovery Right - United States Dollar

ROADRUNNER TRANS SYS INC by Roadrunner Transportation Systems, Inc.

Roadrunner Transportation Systems Inc

REFINED ENERGY CORP by Refined Energy Corp.

Refined Energy Corp

Regal Rexnord Corp

BMO Capital analyst John Kim maintains BXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) with a Outperform and raises the price target from $85 to $86.

Price Target

Analyst Ratings

BMO Capital Maintains Outperform on BXP, Raises Price Target to $86

Key Transaction Terms
Under the terms of the Merger Agreement, a merger subsidiary incorporated in Nevada as a PubCo subsidiary will merge with and into Impact BioMedical, with Impact BioMedical being the surviving entity. Simultaneous with or immediately following the merger, PubCo shall acquire all of the issued and outstanding shares of Dr Ashleys Bio Labs Limited, a Cayman Islands exempted company holding all shares of Dr. Ashleys. As a result of the Transaction, Impact BioMedical and Dr. Ashleys shall become wholly-owned subsidiaries of PubCo. Upon closing, the PubCo will be operated by the management team of Dr Ashleys, with a new Board of Directors to be assembled by Dr Ashleys.
The Boards of Directors of both Dr Ashleys and Impact BioMedical have unanimously approved the proposed Transaction, subject to, among other things, approval by Impact BioMedical's shareholders, and satisfaction (or waiver, as applicable) of the conditions provided in the Merger Agreement, including regulatory approvals and other customary closing conditions, including an effective registration statement on Form F-4 or S-4 in connection with the proposed Transaction being declared effective by the U.S. Securities and Exchange Commission (the "SEC") and the approval of listing applications with the New York Stock Exchange.
Additional information about the proposed Transaction, including a copy of the Merger Agreement, will be provided in a Current Report on Form 8-K to be filed by Impact BioMedical with the SEC and available at <a href="http://www.sec.gov/">www.sec.gov</a>. Additional information about the proposed Transaction will be described in the registration statement on Form F-4 or S-4, which will be filed by the newly formed PubCo with the SEC.

Impact BioMedical And Dr Ashleys Limited Announce Merger And Share Exchange Agreement; Dr. Ashleys To Acquire Impact BioMedical Through A Reverse Merger

JP Morgan analyst Daniel Politzer initiates coverage on Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) with a Overweight rating and announces Price Target of $116.

Initiation

CHDN

JP Morgan Initiates Coverage On Churchill Downs with Overweight Rating, Announces Price Target of $116

Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Tel Aviv Sourasky Medical Center (TASMC), Tel Aviv, Israel, as an additional clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This expansion follows the recent enrollment of the first patient in the trial, announced on June 5, 2025, marking a significant milestone in the development of CMND-100.
The study at Tel Aviv Sourasky Medical Centerwill be led by Dr. David Zeltser, Director of the Emergency Medicine Department. Tel Aviv Sourasky Medical Center joins other prestigious institutions participating in the trial, including Yale School of Medicine's Department of Psychiatry, Johns Hopkins University School of Medicine in the United States. The inclusion of Tel Aviv Sourasky Medical Center further strengthens Clearmind's clinical network, enhancing the trial's capacity to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring its potential to reduce alcohol cravings and consumption in patients with AUD.

CMND

Clearmind Adds Tel Aviv Hospital to Psychedelic Drug Trial for Alcohol Use Disorder

CARM

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

SPTN

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ("Dr Ashleys"), and Impact BioMedical Inc. ("Impact BioMedical") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American ("Impact BioMedical", together with Dr Ashleys, the "Parties"), are pleased to announce the execution of a merger and share exchange agreement (the "Merger Agreement") on June 21, 2025 to enter into a strategic merger transaction (the "Transaction"). Upon closing of the Transaction, Dr. Ashleys will acquire Impact BioMedical through a reverse merger that will result in a newly formed combined entity (the "PubCo") traded on the NYSE American under the name "Dr Ashleys Limited."
The Transaction marks a strategic move that underscores the growing importance of innovation and collaboration in the biomedical industry. With Dr Ashleys' global reach and financial capabilities, the potential for Impact BioMedical's patents to reach the market has never been greater.
Statements from Leadership
Dr. Kanans Visvanats, Director of Dr. Ashleys Limited, stated: "This merger represents a significant milestone in our journey to bring innovative pharmaceutical treatments to patients worldwide. By integrating Impact Biomedical's impressive&nbsp;IP portfolio into our R&amp;D efforts, we are poised to accelerate the development of groundbreaking therapies and expand our Impact on global health."
Frank D. Heuszel, CEO of Impact Biomedical Inc., commented: "We are thrilled to join forces with Dr. Ashleys Limited. Their global reach and financial strength will provide the resources and infrastructure needed to bring our innovations to market, ultimately benefiting people around the world."
Key Transaction Terms
Under the terms of the Merger Agreement, a merger subsidiary incorporated in Nevada as a PubCo subsidiary will merge with and into Impact BioMedical, with Impact BioMedical being the surviving entity. Simultaneous with or immediately following the merger, PubCo shall acquire all of the issued and outstanding shares of Dr Ashleys Bio Labs Limited, a Cayman Islands exempted company holding all shares of Dr. Ashleys. As a result of the Transaction, Impact BioMedical and Dr. Ashleys shall become wholly-owned subsidiaries of PubCo. Upon closing, the PubCo will be operated by the management team of Dr Ashleys, with a new Board of Directors to be assembled by Dr Ashleys.
The Boards of Directors of both Dr Ashleys and Impact BioMedical have unanimously approved the proposed Transaction, subject to, among other things, approval by Impact BioMedical's shareholders, and satisfaction (or waiver, as applicable) of the conditions provided in the Merger Agreement, including regulatory approvals and other customary closing conditions, including an effective registration statement on Form F-4 or S-4 in connection with the proposed Transaction being declared effective by the U.S. Securities and Exchange Commission (the "SEC") and the approval of listing applications with the New York Stock Exchange.

IPOs

Dr Ashleys to Go Public via Merger With Impact BioMedical in NYSE Deal

JP Morgan analyst Daniel Politzer initiates coverage on Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) with a Neutral rating and announces Price Target of $79.

JP Morgan Initiates Coverage On Boyd Gaming with Neutral Rating, Announces Price Target of $79

Crescent Energy Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) ("we" or "our") announced today that, subject to market conditions, its indirect subsidiary Crescent Energy Finance LLC (the "Issuer") intends to offer for sale in a private placement pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the "Securities Act"), to eligible purchasers, $500 million aggregate principal amount of Senior Notes due 2034 (the "Notes"). The Notes will be guaranteed on a senior unsecured basis by all of the Issuer's subsidiaries that guarantee the Issuer's existing notes and the indebtedness under its revolving credit facility (the "revolving credit facility").
The Issuer intends to use the net proceeds from this offering, together with additional borrowings under the revolving credit facility and cash on hand, if needed, to fund the tender offer to purchase for cash up to $500 million aggregate principal amount of the Issuer's outstanding 9.250% Senior Notes due 2028 (the "2028 Notes"), pursuant to the tender offer that commenced concurrently with this offering (the "Tender Offer"), and any fees and expenses in connection therewith or with this offering. Any portion of the net proceeds from this offering that is not used to fund the consummation of the Tender Offer will instead be used to repay amounts outstanding under the revolving credit facility or for general corporate purposes. This offering is not contingent on the consummation of the Tender Offer. The Tender Offer is subject to the satisfaction of certain conditions, including, but not limited to, the completion of this offering.

Offerings

CRGY

Crescent Energy Plans $500M Bond Sale to Help Refinance High-Interest 2028 Notes

With social media oversharing, ubiquitous data brokers, and polarizing public discourse being the new norm, the online privacy of high-ranking executives isn't just a personal matter anymore. It's a corporate concern. CEOs, CFOs, and other public-facing business leaders are increasingly in the crosshairs of executive doxxing, the act of publishing personally identifiable information online with malicious intent.
While doxxing was once largely associated with internet activism or personal vendettas, it's now overlapping with the business world in disconcerting ways. From politically motivated campaigns to financially driven harassment, executives are being exposed and exploited through their digital footprints. And let's face it: companies are bearing the brunt of it.
<h2 class="wp-block-heading">When Executive Privacy Becomes a Corporate Risk</h2>
The reputational damage and security risks associated with doxxing can be staggering. In some cases, an executive's leaked address or family member's name has led to real-world threats, social engineering attempts, or disruptive protests. Even when these incidents don't escalate into physical danger, they can consume resources, <a href="https://www.benzinga.com/news/24/06/39175485/michael-cohens-family-doxxed-after-trumps-hush-money-conviction-says-ex-trump-attorney-what-sad-time">spark media blowback</a>, and erode stakeholder trust.
For publicly traded companies, such episodes can potentially have financial repercussions. Investor confidence wavers when leadership appears vulnerable. This is especially true for industries where the perception of security and discretion is paramount, such as finance, tech, and defense.
Moreover, a growing number of targeted cyberattacks begin with publicly available data scraped from people-search sites, social platforms, or public records. This makes the digital footprint of corporate leaders a natural entry point for malicious actors.
<h2 class="wp-block-heading">Why Traditional Security Strategies Fall Short</h2>
Most corporations invest heavily in cybersecurity infrastructure, physical access controls, and high-level legal protections for the people upstairs. These strategies tend to focus on the perimeter, shielding company data, devices, and networks. While worthwhile, such mechanisms often turn a blind eye to the ecosystem of personal data scattered across the internet. And that's precisely where doxxers look first.
Here's some food for thought: numerous data broker sites legally aggregate and sell personal information such as home addresses, previous residences, email addresses, and more. This information is typically compiled without consent and made publicly searchable, offering a dossier for anyone with a grudge or a motive.
Alarmingly, senior executives can be clueless about how exposed their personal details are, and few have the time or know-how to address this on their own.
<h2 class="wp-block-heading">Proactive Privacy as a New Breed of Executive Defense</h2>
To tackle this threat, more organizations are beginning to intertwine personal data removal strategies into their broader executive protection plans. These strategies aim to eliminate or suppress personal details from data broker sites, people-search platforms, and other online repositories. The options range from niche consulting firms to privacy services that specialize in large-scale data removal.
For instance, platforms that automate the process of requesting <a href="https://blog.incogni.com/opt-out-guides/">opt out</a> from dozens (sometimes hundreds) of data brokers can save executives the time and hassle of interacting with each site individually. This approach can be integrated into onboarding or risk mitigation programs for C-level roles and public-facing personnel.
The counterintuitive part is that data removal isn't necessarily reactive. It can be preventive. Regular monitoring and removal reduce the surface area that attackers or agitators can exploit. This makes executive doxxing attempts harder and less effective from the get-go.
<h2 class="wp-block-heading">Building a Culture of Privacy Awareness at the Top</h2>
Organizations looking to protect their leadership must foster a culture of privacy mindfulness, and the process starts from the top. Executives often serve as both brand ambassadors and decision-makers. That means their personal behavior online can have cascading effects on the company.
That being said, key steps to institutionalize enterprise-wide privacy resilience include:
<ul class="wp-block-list">
<li>Training and awareness: C-suite members should understand the mechanics of executive doxxing and the ways their digital presence fuels personal and corporate risk.</li>
<li>Audit and visibility: Conduct regular assessments of what personal data is publicly available on executives and directors.</li>
<li>Policy integration: Incorporate privacy protocols into contracts and executive onboarding procedures.</li>
<li>Digital compartmentalization: Encourage leaders to keep personal accounts, devices, and apps separate from business-facing ones, and to <a href="https://support.microsoft.com/en-us/topic/the-dangers-of-oversharing-79330a32-4ee1-433a-812e-fe4bb3d34511">avoid oversharing online</a>.</li>
</ul>
It's not about asking leaders to become digital recluses. Instead, it's about understanding that the countermeasures for personal data exposure are just as important as protecting internal systems.
<h2 class="wp-block-heading">From Afterthought to Business Commitment</h2>
The line between personal privacy and organizational security continues to blur. This is increasingly evident in the area of executive doxxing. As visibility increases for public-facing professionals, so does the need to anticipate and deflect potential attacks on their personal lives.
For companies, this means that protecting executives goes beyond installing cameras or monitoring access logs. It's about limiting how much of their data can be pulled up with a few clicks and a search engine. The less exposed the individual, the safer the organization.
Incorporating privacy tools and data removal services into your company's executive protection playbook is a strategic foresight rather than an overkill. It <a href="https://www.benzinga.com/news/events/24/08/40554802/from-data-centers-to-the-cloud-transition-creates-new-challenges-for-it-pros-analyst-says">acknowledges</a> that the most sensitive information isn't necessarily stored on a company server these days. Sometimes, it's a home address listed on page three of a people-search website, waiting for the wrong person to find it.

Opinion

General

When C-Suite Privacy Becomes A Corporate Risk: How To Combat Executive Doxxing

JP Morgan analyst Daniel Politzer initiates coverage on Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) with a Overweight rating and announces Price Target of $101.

JP Morgan Initiates Coverage On Wyndham Hotels & Resorts with Overweight Rating, Announces Price Target of $101

JP Morgan analyst Daniel Politzer initiates coverage on Sunstone Hotel Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHO#NYSE">SHO</a>) with a Underweight rating and announces Price Target of $8.

JP Morgan Initiates Coverage On Sunstone Hotel Invts with Underweight Rating, Announces Price Target of $8

BMO Capital analyst John McNulty downgrades Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from Market Perform to Underperform and lowers the price target from $29 to $22.

Downgrades

BMO Capital Downgrades Dow to Underperform, Lowers Price Target to $22

Siyata Mobile Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>, SYTAW)) ("Siyata" or the "Company"), a global developer and vendor of mission-critical Push-to-Talk over Cellular (PoC) handsets and accessories, today announced that Core Gaming, a rising innovator in AI-driven creative technologies, who it recently signed a definitive merger agreement with, is experiencing continued momentum with its innovative AI COMIC app.
&nbsp;
In less than one year, combined user numbers of AI COMIC in Japan and South Korea have jumped from 2,500 to over 32,000, a 13x increase, while those countries' share of total global users rose from 4.12% to 14.38%.
"AI COMIC's breakout success in Japan and South Korea is a powerful validation of our strategic vision," said Aitan Zacharin, CEO of Core Gaming. "Return on investment in the region has more than tripled, driven by targeted localization efforts such as a language-optimized user interface. Just as important, the virality we are seeing through widely used platforms like TikTok and Facebook underscores how deeply users are engaging with our product."
Launched to broad interest, AI COMIC blends next-gen AI capabilities with a uniquely immersive user experience. The app empowers users to transform everyday visuals into vivid anime-style content through features such as AI-generated video, personalized avatars, manga scene recreation, time-lapse aging and realistic face swaps.
Zacharin continued, "AI COMIC runs on a robust technological foundation built on our proprietary Compute Pool System, multimodal generative AI models and a scalable cloud orchestration architecture that is redefining content creation and distribution. Importantly, our goal is not just to build apps. We are building a robust, scalable AI infrastructure designed to power creative expression on a global scale. AI COMIC is only the beginning."
Technology Platform: A Breakthrough AI Engine
While AI COMIC continues to attract headlines and users, the underlying technology is the true differentiator. To support rapid growth and creative demand, Core Gaming built a smart, cloud- based infrastructure that delivers scalable AI performance while keeping costs efficient. This foundation enables the platform to streamline game asset creation—from automated scene and character generation to fast, high-quality animations and ad creatives—helping content teams iterate faster and bring ideas to life with minimal effort.
Core Gaming's AI infrastructure is designed around three core pillars:
<ul>
<li>Compute Pool System (CPS) is a dynamic AI task distribution engine that allocates computational resources across workloads in real time. CPS ensures optimal throughput for video generation, avatar rendering and real-time user interactions—without overprovisioning infrastructure. &nbsp;</li>
<li>Multimodal Generative Models that process and synthesize visual, text and audio inputs simultaneously, enabling complex creative outputs such as dialogue-driven animation, mood-based styling, and high-resolution content generation tailored to the user's intent. &nbsp;</li>
<li>Proprietary BigP Backend and Cloud Orchestration serves as the orchestration layer for model training, inference pipelines and content delivery. Integrated with a globally distributed cloud framework, it scales elastically to meet creative surges whether from new user spikes or major feature rollouts.</li>
</ul>

SYTA

Siyata's Merger Partner Core Gaming Sees AI Comic App Users Surge 13x in Japan and South Korea

JP Morgan analyst Daniel Politzer initiates coverage on Ryman Hospitality Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Overweight rating and announces Price Target of $117.

JP Morgan Initiates Coverage On Ryman Hospitality Props with Overweight Rating, Announces Price Target of $117

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Saturday announced detailed results from the ACHIEVE-1 Phase 3 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diet and exercise alone</a>.
The company released its topline data <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential" rel="noreferrer noopener">from the trial in April</a>.
At 40 weeks, all three doses (3 mg, 12 mg, 36 mg) of orforglipron achieved the primary endpoint of superior A1C reduction.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/46003836/eli-lillys-1-3-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst</a>
In addition, the 12 mg and 36 mg doses showed clinically meaningful and statistically significant reductions in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46041936/lillys-oral-glp-1-orforglipron-showed-compelling-efficacy-and-a-safety-profile-consistent-with-inj" rel="noreferrer noopener">body weight vs. placebo</a>.
In the study, orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks, lowering A1C by 1.3% to 1.6% from a baseline of 8.0% for the efficacy estimand.
In key secondary endpoints, up to 76.2% of participants taking orforglipron achieved the ADA treatment target A1C of &lt;7%, 66.0% achieved an A1C of ≤6.5%, and 25.8% achieved &lt;5.7%, defined as a normal A1C value.
Improvements in A1C were observed as early as four weeks and were accompanied by similar reductions in fasting serum glucose.
In another key secondary endpoint, participants taking the highest dose of orforglipron lost an average of 16.0 lbs (7.9%). 
While participants in ACHIEVE-1 did not appear to reach a weight plateau, longer-duration trials, such as the ATTAIN trials, will provide a comprehensive evaluation of the safety and efficacy of orforglipron for obesity.
While the tolerability profile was in line with the incretin class, William Blair highlights that at the highest dose, nausea, vomiting, and constipation did not appear to subside over time, in contrast with its peptide GLP-1 receptor agonist counterparts.
&#8220;We are less bullish about the prospects of orforglipron in this setting for two reasons: early plateauing and persistent side effects,&#8221; said analyst Andy Hsieh.
<h2 class="wp-block-heading">Once-Weekly Insulin Efsitora</h2>
In addition to the orforglipron data, Eli Lilly also shared promising results for its investigational once-weekly insulin, efsitora.
On Sunday, Eli Lilly announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin <a href="https://www.benzinga.com/pressreleases/25/06/n46043947/lillys-once-weekly-insulin-efsitora-alfa-demonstrated-a1c-reduction-and-a-safety-profile-consisten" target="_blank" rel="noreferrer noopener">and mealtime insulin, respectively</a>.
Eli Lilly released topline results from the QWINT-1 and QWINT-3 trials <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40731728/eli-lillys-once-weekly-insulin-shows-non-inferior-blood-sugar-reduction-vs-frequently-used-daily-" rel="noreferrer noopener">in September 2024</a>.
In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin.
In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand.
In the trial, efsitora was titrated to four fixed doses at four-week intervals, as needed for blood glucose control.
In QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec at week 26 for the efficacy estimand. In QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine.
Lilly plans to submit&nbsp;efsitora for adults with type 2 diabetes to global regulatory agencies by the end of this year.
In QWINT-1, efsitora resulted in approximately 40% fewer hypoglycemic events compared to insulin glargine, with estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure of 0.50 with efsitora vs. 0.88 with insulin glargine at 52 weeks. In QWINT-3, these rates were 0.84 with efsitora vs. 0.74 with insulin degludec at 78 weeks.
In QWINT-4, estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 6.6 with&nbsp;efsitora vs. 5.9 with insulin glargine at 26 weeks.
Across the three trials, efsitora demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for type 2 diabetes.
Price Action: LLY stock is trading lower by 0.19% to $761.25 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/46036868/obesity-drugs-help-with-weight-loss-but-are-adding-fat-elsewhere" target="_blank" rel="noreferrer noopener">Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere</a></li>
</ul>
Image via Shutterstock

Biotech

Large Cap

Health Care

Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns

Guardforce AI Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFAI#NASDAQ">GFAI</a>) on Monday <a target="_blank" href="https://www.benzinga.com/topic/ai" rel="noreferrer noopener">announced that its</a> subsidiary, Guardforce Cash Solutions Security (Thailand) Company Limited (GFCS), has won a three-year renewal with Government Savings Bank (GSB).
GSB one of Thailand&#8217;s state-owned banks adn the renewal deal is effective from June 1, 2025, through May 31, 2028.
This fourth consecutive renewal represents a decade-long partnership between the company and GSB.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/12/42314074/exclusive-guardforce-ai-taps-librum-technologies-to-boost-ai-agent-capabilities" rel="noreferrer noopener">Guardforce AI Taps Librum Technologies To Boost AI Agent Capabilities</a>
Under the renewed agreement, GFCS will continue to provide secure and efficient cash-in-transit and maintenance services for GSB&#8217;s ATM network across Thailand&#8217;s upcountry regions, which covers most of the company&#8217;s ATM services currently handled.
With this renewal, Guardforce AI will secure stable and predictable revenue streams over the next three years, providing the company with a solid financial foundation to invest in innovation and expand its AI-driven solutions, the company said.
In January, GFCS <a target="_blank" href="https://www.benzinga.com/news/25/01/43262471/exclusive-guardforce-ai-expands-partnership-with-government-savings-bank-in-thailand" rel="noreferrer noopener">renewed key contracts</a> with its long-time customer GSB in Thailand. Under two three-year multi-million-dollar contracts, GFCS continued to deliver cash center operations and secure logistics services for coins.
Price Action: GFAI stock closed lower by 3.33% at $1.16 Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46040754/amazons-powerful-aws-custom-chip-to-get-an-upgrade-why-is-it-important" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Powerful AWS Custom Chip To Get An Upgrade &#8211; Why Is It Important?</a></li>
</ul>
Photo via Company

Market-Moving Exclusives

Exclusives

GFAI

GFAIW

EXCLUSIVE: Guardforce AI Renews 3-Year Deal With Thailand's Government Savings Bank

EXCLUSIVE: Guardforce AI Tells Benzinga 'Ensuring Stable Revenue Streams to Drive Future AI Innovations'

EXCLUSIVE: Guardforce AI Tells Benzinga Co. Strengthens Decade-Long Client Relationships By Securing Long-Term Contract With Government Savings Bank

WIIM

Hims & Hers Health, Inc. Class A Common Stock

Comments

Richtech Robotics

Richtech Robotics (RR) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL